GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (LSE:IMM) » Definitions » Institutional Ownership

ImmuPharma (LSE:IMM) Institutional Ownership : 5.20% (As of May. 05, 2024)


View and export this data going back to 2003. Start your Free Trial

What is ImmuPharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ImmuPharma's institutional ownership is 5.20%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ImmuPharma's Insider Ownership is 9.27%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ImmuPharma's Float Percentage Of Total Shares Outstanding is 0.00%.


ImmuPharma Institutional Ownership Historical Data

The historical data trend for ImmuPharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma Institutional Ownership Chart

ImmuPharma Historical Data

The historical data trend for ImmuPharma can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 4.50 4.50 5.49 5.49 5.49 5.49 5.49 5.20 5.20 5.20

ImmuPharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


ImmuPharma (LSE:IMM) Business Description

Traded in Other Exchanges
Address
One Bartholomew Close, London, GBR, EC1A 7BL
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.

ImmuPharma (LSE:IMM) Headlines

No Headlines